Sensible use of tumor markers;Sinnvoller einsatz von tumormarkern

LaboratoriumsMedizin

Volumn 32, Issue 5, 2008, Pages 339-360

  Stieber, Petra ^a   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Dependency on kit used; Follow up care; Indications; Influencing factors; Interfering factors; Interpretation; Oncological biomarker; Primary diagnosis; Prognosis; Screening; Sensitivity; Specificity; Therapy control; Tumor marker

Indexed keywords

CYTOKERATIN; HORMONE; MUCIN; PROSTATE SPECIFIC ANTIGEN; THYROGLOBULIN; TUMOR ANTIGEN; TUMOR MARKER;

BIOPSY; BLOOD COMPONENT; CANCER DIAGNOSIS; CANCER THERAPY; CATABOLISM; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; ENDOSCOPY; FOLLOW UP; KIDNEY FUNCTION; LIVER FUNCTION; METASTASIS; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; REVIEW; SOLID TUMOR; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; URETER CATHETER;

EID: 55249083099     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2008.015     Document Type: Review

References (48)

1. European Group on Tumour Markers (EGTM): Consensus Recommendations. Anticancer Research 1999;19:2785-820. (http://egtm.web.med.uni-muenchen.de/).
2. Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Wittliff JL. Practice Guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, editors. Tumor Markers - Physiology, pathobiology, technology and clinical applications. Washington 2002: AACC Press; 2002:33-63. (http://www.nacb.org/LMPG/Monograph_TumorMarkers. pdf).
3. Sturgeon C. Practice guidelines for tumor marker use in the clinic. ClinChem 2002;48:1151-9.
4. Tumormarker/Maligne Erkrankungen. In: Thomas L, Hrsg. Labor und Diagnose, 5. Auflage, TH-Books Verlagsgesellschaft mbH, Frankfurt/Main, (Deutschland) 2005:1291-375.
5. Stieber P, Schalhorn A. Laborparameter. In: Guder/Nolte, Hrsg. Das Laborbuch für Klinik und Praxis, Urban & Fischer Verlag München (Deutschland) 2005.
6. Stieber P, Nagel D, Heinemann V. Tumor markers in metastatic breast cancer: high tumor specificity within the reference range. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings 2006;24(Suppl 18):1055.
7. Umehara Y, Kimura T, Yoshida M, Oba N, Harada Y. Comparison of doubling times of serum carcinoembryonic antigen produced by various metastatic lesions in recurrent gastric and colorectal carcinomas. Cancer 1993;71:4055-9.
8. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer (Cochrane Review). In: The Cochrane Library, Issue 2, 2004, Chichester, UK: John Wiley & Sons, Ltd.
9. Rosen M, Chan L, Ceart RW Jr, Vukasin P, Anthone G. Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum 1998;40:1116-26.
10. Anonymous: ASCO 2006 Update recommendations for the use of TM in gastrointestinal cancer. J Clin Oncol 2006; 33:5313-27.
11. Duffy M, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43:1348-60.
12. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American joint committee on cancer prognostic factors consensus conference. Colorectal working group. Cancer 2000;88:1739-57.
13. Hofmann D, Nagel D, Lau-Werner U, Wichmann MW, Hornung HM, Stenman UH, et al. Prognosis in non-metastatic colorectal cancer: multivariate evaluation of preoperative levels of six tumor markers in addition to clinical parameters. J Lab Med 2007;31:76-85.
14. Klapdor R, Aronsson AC, Duffy MJ, Hansson LO, Khalifa R, Lamerz R. Tumor markers in gastrointestinal cancers: EGTM recommendations. Anticancer Res 1999;19:2811-5.
15. Goggins M, Koopmann J, Yang D, Canto MI, Hruban RH. National Academy of Clinical Biochemistry (NACB) guidelines for the use of tumor markers in pancreatic ductal adenocarcinoma. 2006, (http://www.nacb.org/lmpg/tumor/ chp3i_pancreatic.doc).
16. Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998;45:253-9.
17. Ishii H, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997;44:279-83.
18. Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 1998;77:325-8.
19. Heinemann V, Schermuly MM, Stieber P, Schulz L, Jungst D, Wilkowski R, et al. CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res 1999;19:2433-5.
20. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006;70:255-64.
21. Lamerz R, Hayes P, Hoffmann RT, Löhe F, Shiratori Y, Taketa K. National academy of clinical biochemistry guidelines for the use of tumor markers in primary liver cancer. 2006, (http://www.nacb.org/lmpg/tumor/ chp3d_liver.doc).
22. Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, et al. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res 1997;17:2903-6.
23. Bonfrer JMG, Louhimo J. National academy of clinical biochemistry guidelines for the use of tumor markers in gastric cancer. 2006, (http://www.nacb.org/lmpg/tumor/chp3g_gastric.doc).
24. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in Breast Cancer - European Group on Tumor Markers Recommendations. Tumour Biol 2005; 19:2803-5.
25. Duffy MJ, Esteva FJ, Harbeck N, Molina R, Hayes DF. National academy of clinical biochemistry guidelines for the use of tumor markers in breast cancer. 2006, (http://www.nacb.org/lmpg/tumor/chp3f_breast.doc).
26. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny G, Schmitt UM, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002;86:1217-22.
27. Lässig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, Stieber P. CEA und CA 15-3 beim fortgeschrittenen Mammakarzinom. J Lab Med 2007;31:70-5.
28. Stieber P, Lässig D, Heinemann V, Untch M, Kahlert S, Nagel D. Kinetics of CEA and CA 15-3 correlate with response in patients undergoing chemotherapy for metastatic breast cancer. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. 2007;25(Suppl 18):1087.
29. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005;7:R436-R43.
30. Stemmler J, Stieber P, Lässig D, Heinemann V. Re-evalution of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab. Onkologie 2005;28:95-7.
31. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJS, Soletormos G, Torre GC, et al. CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Cancer 2005;15:679-91.
32. Chan DW, Shih IM, Sokoll LJ, Bast RC. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Ovarian Cancer. 2006, (http://www.nacb.org/lmpg/tumor/chp3e_ovarian.doc).
33. Rustin GJS, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545-51.
34. Rustin GJS, Marples M, Neltstrop AE, et al. Use of CA 125 to define progression of ovarian cancer in patients with perstistently elevated levels. J Clin Oncol 2001;10:4054-7.
35. Stieber P, Aronsson AC, Bialk P, Kulpa J, Lamerz R, Molina R. Recommendations for the use of tumour markers in lung cancer Subgroup of the "European Group on Tumour Markers (EGTM)". Anticancer Res 1999;19:2817-9.
36. Stieber P, Hatz R, Holdenrieder S, Molina R, Nap M, von Pawel J, et al. National academy of clinical biochemistry guidelines for the use of tumor markers in lung cancer, 2006 http://www.nacb.org/lmpg/tumor/chp3p_lung.doc.
37. Stieber P, Yamaguchi K. ProGRP enables diagnosis of small cell lung cancer. In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications Hrsg.: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK. AACC Press Washington, USA, 2002,517-22 (http://www.nacb.org/LMPG/ Monograph_TumorMarkers.pdf).
38. Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, et al. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem 1994;32:189-99.
39. Molina R, Filella X, Auge JM, Fuentes R Bover I, Rifa J, et al. Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. comparison with the main clinical and pathological prognostic factors. Tumor Biology 2003;24:209-18.
40. Stenman UH, Lamerz R, Looijenga LH, Bosl GJ. National academy of clinical biochemistry guidelines for the use of tumor markers in testicular cancer, 2006, (http://www.nacb.org/lmpg/tumor/chp3a_testicular.doc).
41. International germ cell collaborative group (IGCCCG). International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancer. J Clin Oncol 1997;15:594-603.
42. Gerl A, Lamerz R, Clemm C, Mann K, Wilmanns W. Does serum tumor marker half life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res 1996;2:1565-70.
43. Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001;19:2534-41.
44. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-99.
45. Schambeck CM, Schmeller N, Stieber P, Jansen HM, Pahl H, Schneider W, Fateh-Moghadam. Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer. Urology 1995;46:195-9.
46. Sturgeon CM, Ellis AR. Improving the comparability of immunoassays for prostate-specific antigen (PSA): progress and problems. Clin Chim Acta 2007;381:85-92.
47. Hasholzner U, Stieber P, Meier W, Lamerz R. Value of HAMA-determination in clinical practice - an overview. Anti-cancer Res 1997;17:3055-8.
48. Dresse M, Nagel D, Ganser EM, Davis G, Dowell B, Doss R, et al. Dependence of TIMP-1 plasma levels on pre-analytical specimen handling. Tumor Biol 2008;29:35-40.